A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...
Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...
GlobalData on MSN6d
MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drugCompared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...
A replay of the webcast Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for ...
Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Mural Oncology in a research ...
Relacorilant plus nab-paclitaxel chemotherapy reduced the risk of disease progression by 30% compared with nab-paclitaxel alone. Treatment with relacorilant plus nab-paclitaxel improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback